{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:01:46Z","timestamp":1778144506502,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to establish the population protein binding parameters of valproic acid (VPA) in patients with epilepsy receiving VPA monotherapy and those receiving VPA combined with other antiepileptic drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One hundred and thirty nine data sets from 63 Japanese patients with epilepsy were analysed. These patients were separated into two groups: VPA monotherapy and VPA combined with other binding-sensitive antiepileptic drugs, including phenytoin, clonazepam, clobazam, carbamazepine and phenobarbital (VPA polytherapy). The population protein-binding parameters of VPA were obtained by non-linear least-squares method in each group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The mean (95% confidence interval) dissociation constants were 38.9 \u00b5m (33.2\u201344.6 \u00b5m) and 36.9 \u00b5m (26.7\u201347.1 \u00b5m), and the numbers of binding sites were 1.36 (1.27\u20131.44) and 1.33 (1.19\u20131.47) in the monotherapy and polytherapy groups, respectively. No significant differences in the binding parameters of VPA to serum albumin were observed between the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The steady-state serum albumin binding of VPA in Japanese patients with epilepsy is not affected by co-administration of other antiepileptic drugs. These findings suggest that serum VPA concentration is stable at the steady state with regard to interaction by protein binding, even when other antiepileptic drugs with moderate-to-high binding properties are co-administered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.2042-7158.2011.01282.x","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T11:49:55Z","timestamp":1307620195000},"page":"976-981","source":"Crossref","is-referenced-by-count":13,"title":["No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy"],"prefix":"10.1093","volume":"63","author":[{"given":"Yosuke","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Takeyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital , Hasama-machi, Oita,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"2024103013284303700_cit1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0140-6736(90)91886-F","article-title":"Established anticonvulsants and treatment of refractory epilepsy","volume":"336","author":"Brodie","year":"1990","journal-title":"Lancet"},{"key":"2024103013284303700_cit2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0140-6736(90)92025-D","article-title":"Treatment of epilepsy and febrile convulsions in children","volume":"336","author":"Rylance","year":"1990","journal-title":"Lancet"},{"key":"2024103013284303700_cit3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013284303700_cit4","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1345\/aph.1G167","article-title":"Acute hyperammonemic coma with chronic valproic acid therapy","volume":"39","author":"Cuturic","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2024103013284303700_cit5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0269881106065101","article-title":"A case of pancytopenia","volume":"20","author":"Keown","year":"2006","journal-title":"J Psychopharmacol"},{"key":"2024103013284303700_cit6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.1983.tb02179.x","article-title":"Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing","volume":"16","author":"Rapeport","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013284303700_cit7","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/WNL.42.5.988","article-title":"Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy","volume":"42","author":"Lenn","year":"1992","journal-title":"Neurology"},{"key":"2024103013284303700_cit8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"2024103013284303700_cit9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","article-title":"Nonlinear pharmacokinetics: clinical implication","volume":"20","author":"Ludden","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"2024103013284303700_cit10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00007691-199706000-00007","article-title":"Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor","volume":"19","author":"Dasgupta","year":"1997","journal-title":"Ther Drug Monit"},{"key":"2024103013284303700_cit11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ajcp\/101.3.349","article-title":"Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds","volume":"101","author":"Dasgupta","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"2024103013284303700_cit12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00007691-199606000-00011","article-title":"Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions","volume":"18","author":"Dasgupta","year":"1996","journal-title":"Ther Drug Monit"},{"key":"2024103013284303700_cit13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/00007691-199612000-00005","article-title":"Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors","volume":"18","author":"Dasgupta","year":"1996","journal-title":"Ther Drug Monit"},{"key":"2024103013284303700_cit14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00044011-199815020-00008","article-title":"Factors affecting the free plasma fraction of phenytoin in patients with epilepsy","volume":"15","author":"Jim\u00e9nez","year":"1998","journal-title":"Clin Drug Investig"},{"key":"2024103013284303700_cit15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1742-7843.2006.pto_309.x","article-title":"Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients","volume":"99","author":"Joerger","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024103013284303700_cit16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cpt1974153276","article-title":"Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease","volume":"15","author":"Hooper","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"2024103013284303700_cit17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/clpt.1984.43","article-title":"Clonazepam serum protein binding during development","volume":"35","author":"Pacifici","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"2024103013284303700_cit18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","article-title":"Kinetics and metabolism of clobazam in animals and man","volume":"7","author":"Volz","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013284303700_cit19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00045391-199610000-00005","article-title":"Evaluation of unbound serum carbamazepine and carbamazepine-10,11-epoxide concentration prediction methods in polytherapy adult patients with epilepsy","volume":"3","author":"Kodama","year":"1996","journal-title":"Am J Ther"},{"key":"2024103013284303700_cit20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0387-7604(85)80134-0","article-title":"Effect of serum albumin on free fractions of phenobarbital and valproic acid in patients with convulsive seizures","volume":"7","author":"Sadahiro","year":"1985","journal-title":"Brain Dev"},{"key":"2024103013284303700_cit21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOP.0b013e32805e879a","article-title":"Carnitine as an antidote for acute valproate toxicity in children","volume":"19","author":"Russell","year":"2007","journal-title":"Curr Opin Pediatr"},{"key":"2024103013284303700_cit22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ajem.2005.02.015","article-title":"L-carnitine was safely administered in the setting of valproate toxicity","volume":"23","author":"LoVecchio","year":"2005","journal-title":"Am J Emerg Med"},{"key":"2024103013284303700_cit23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetics analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobiodyn"},{"key":"2024103013284303700_cit24","first-page":"364","article-title":"Protein binding of L-carnitine family components","volume":"3","author":"Marzo","year":"1991","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024103013284303700_cit25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2710.2008.00885.x","article-title":"Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children","volume":"33","author":"Ueshima","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"2024103013284303700_cit26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/59.9.835","article-title":"Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy","volume":"59","author":"Kodama","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"2024103013284303700_cit27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1177\/00912709922011728","article-title":"No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy","volume":"39","author":"Kodama","year":"1999","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2011.01282.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/7\/976\/60234612\/j.2042-7158.2011.01282.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/7\/976\/60234612\/j.2042-7158.2011.01282.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:50:15Z","timestamp":1730314215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/63\/7\/976\/6135534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2011.01282.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,7]]},"published":{"date-parts":[[2011,7,1]]}}}